In addition to retinal diseases, the therapeutic use of Annexin A5 to target PS has been proposed in other ophthalmic diseases [22,23], cancer [17], sepsis [18,24], viral infections including COVID-19 [25,26], inflammatory bowel disease [27], osteoporosis [28], Alzheimer’s disease [13], vaso-occlusive crisis in sickle cell disease [29,30], diabetic skin wounds [16], renal ischemia reperfusion damage [15], and cardiovascular disease [14]. This evidence concerns the gene ANXA5 and viral infectious disease.